← Back to Search

Stem Cell Therapy

Allogeneic adipose derived mesenchymal stem cells for Ischemia Reperfusion Injury

Phase 1
Waitlist Available
Led By Tambi Jarmi, MD
Research Sponsored by Tambi Jarmi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will test if the investigational drug aMSCs can help treat IRI, a condition that can occur after a kidney transplant.

Eligible Conditions
  • Ischemia Reperfusion Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serious Adverse Events (SAEs)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Intra-arterial infusionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via intra-arterial infusion only
Group II: Intra parenchymal injection & Intra-arterial infusionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
Group III: Intra parenchymal injectionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via direct injection into the kidney parenchyma only

Find a Location

Who is running the clinical trial?

Tambi JarmiLead Sponsor
Tambi Jarmi, MDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
University Of Aleppo (Medical School)
University Of Al Hospital (Residency)

Media Library

Allogeneic Adipose Mesenchymal Stem Cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04388761 — Phase 1
Ischemia Reperfusion Injury Research Study Groups: Intra-arterial infusion, Intra parenchymal injection & Intra-arterial infusion, Intra parenchymal injection
Ischemia Reperfusion Injury Clinical Trial 2023: Allogeneic Adipose Mesenchymal Stem Cells Highlights & Side Effects. Trial Name: NCT04388761 — Phase 1
Allogeneic Adipose Mesenchymal Stem Cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04388761 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still accepting new participants for this experiment?

"According to the clinicaltrials.gov database, this experiment has been open for signups since September 28th 2020 and is still recruiting participants as of October 8th 2022."

Answered by AI

How many participants are recruited for this clinical experiment?

"Affirmative. Clinicaltrials.gov attests to this clinical trial's active recruitment, which began on September 28th 2020 and was last updated October 8th 2022; 15 participants are being sought at a single location."

Answered by AI

Is Allogeneic adipose derived mesenchymal stem cell therapy a secure treatment option for individuals?

"Our team at Power rated Allogeneic adipose derived mesenchymal stem cells a 1 on the safety scale because it is in its initial clinical trial stage, with limited data to support both efficacy and harmlessness."

Answered by AI
~0 spots leftby Mar 2025